Current concepts of colorectal cancer resection pathology

Histopathology

Volumn 66, Issue 1, 2015, Pages 102-111

  Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Local excision; Total mesorectal excision

Indexed keywords

ANATOMIC LANDMARK; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL SURGERY; HUMAN; LOCAL EXCISION; MICROSCOPY; PATHOLOGY; PRIORITY JOURNAL; REVIEW; ABDOMINAL SURGERY; COLORECTAL NEOPLASMS; PROCEDURES;

COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS;

EID: 84920972759     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12563     Document Type: Review

References (59)

1. Elferink MA, van Steenbergen LN, Krijnen P et al. Marked improvements in survival of patients with rectal cancer in the netherlands following changes in therapy, 1989-2006. Eur. J. Cancer 2010; 46; 1421-1429.
2. Xie H, Zhou X, Zhuo Z, Che S, Xie L, Fu W. Effectiveness of MRI for the assessment of mesorectal fascia involvement in patients with rectal cancer: a systematic review and meta-analysis. Dig. Surg. 2014; 31; 123-134.
3. Glimelius B, Beets-Tan R, Blomqvist L et al. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J. Clin. Oncol. 2011; 29; 2142-2143.
4. Nagtegaal ID, van de Velde CJ, van der Worp E et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J. Clin. Oncol. 2002; 20; 1729-1734.
5. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC cr07 and NCIC-CTG co16 randomised clinical trial. Lancet 2009; 373; 821-828.
6. Bosch SL, Nagtegaal ID. The importance of the pathologist's role in assessment of the quality of the mesorectum. Curr. Colorectal Cancer Rep. 2012; 8; 90-98.
7. Barnajian M, Pettet D III, Kazi E, Foppa C, Bergamaschi R. Quality of total mesorectal excision and depth of circumferential resection margin in rectal cancer: a matched comparison of the first 20 robotic cases. Colorectal Dis. 2014; 16; 665-666.
8. Fernandez Ananin S, Targarona EM, Martinez C et al. Predicting the pathological features of the mesorectum before the laparoscopic approach to rectal cancer. Surg. Endosc. 2014; Epub ahead of print.
9. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J. Clin. Oncol. 2010; 28; 272-278.
10. West NP, Hohenberger W, Finan PJ, Quirke P. Mesocolic plane surgery: an old but forgotten technique? Colorectal Dis. 2009; 11; 988-989.
11. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol. 2008; 9; 857-865.
12. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J. Clin. Oncol. 2008; 26; 303-312.
13. van de Velde CJ, Boelens PG, Borras JM et al. Eurecca colorectal: multidisciplinary management: European consensus conference colon and rectum. Eur. J. Cancer 2014; 50; 1.e1-1.e34.
14. Gosens MJ, van Krieken JH, Marijnen CA et al. Improvement of staging by combining tumor and treatment parameters: the value for prognostication in rectal cancer. Clin. Gastroenterol. Hepatol. 2007; 5; 997-1003.
15. Nagtegaal ID, Gosens MJ, Marijnen CA, Rutten HJ, van de Velde CJ, van Krieken JH. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J. Clin. Oncol. 2007; 25; 1647-1650.
16. Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. Am. J. Clin. Pathol. 1999; 111; 349-351.
17. Bujko K, Rutkowski A, Chang GJ, Michalski W, Chmielik E, Kusnierz J. Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review. Ann. Surg. Oncol. 2012; 19; 801-808.
18. Rorvig S, Schlesinger N, Martensson NL, Engel S, Engel U, Holck S. Is the longitudinal margin of carcinoma-bearing colon resections a neglected parameter? Clin. Colorectal Cancer 2014; 13; 68-72.
19. Williams NS, Dixon MF, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients' survival. Br. J. Surg. 1983; 70; 150-154.
20. Shirouzu K, Isomoto H, Kakegawa T. Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 1995; 76; 388-392.
21. Morikawa E, Yasutomi M, Shindou K et al. Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis. Colon Rectum 1994; 37; 219-223.
22. Quirke P, Palmer T, Hutchins GG, West NP. Histopathological work-up of resection specimens, local excisions and biopsies in colorectal cancer. Dig. Dis. 2012; 30(Suppl. 2); 2-8.
23. Markl B, Schaller T, Krammer I et al. Methylene blue-assisted lymph node dissection technique is not associated with an increased detection of lymph node metastases in colorectal cancer. Mod. Pathol. 2013; 26; 1246-1254.
24. Borowski DW, Banky B, Banerjee AK et al. Intra-arterial methylene blue injection into ex vivo colorectal cancer specimens improves lymph node staging accuracy: a randomized controlled trial. Colorectal Dis. 2014; 16; 681-689.
25. van Steenbergen LN, van Lijnschoten G, Rutten HJ, Lemmens VE, Coebergh JW. Improving lymph node detection in colon cancer in community hospitals and their pathology department in southern Netherlands. Eur. J. Surg. Oncol. 2010; 36; 135-140.
26. Ng CW, Lieske B, Tan KK. Routine histological sampling of doughnuts post oncologic anterior resection is not necessary. Int. J. Colorectal Dis. 2014; 29; 843-845.
27. Quirke P, Cuvelier C, Ensari A et al. Evidence-based medicine: the time has come to set standards for staging. J. Pathol. 2010; 221; 357-360.
28. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat. Rev. Clin. Oncol. 2012; 9; 119-123.
29. Nagtegaal ID, Tot T, Jayne DG et al. Lymph nodes, tumor deposits, and TNM: are we getting better? J. Clin. Oncol. 2011; 29; 2487-2492.
30. Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 2004; 22; 3408-3419.
31. World Health Organization. World Health Organization classification of tumours of the digestive system. 4th ed. Lyon: IARC Press, 2010.
32. Hugen N, Verhoeven RH, Lemmens VE et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int. J. Cancer 2015; 136; 333-339.
33. Winn B, Tavares R, Fanion J et al. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum. Pathol. 2009; 40; 398-404.
34. Maughan NJ, Morris E, Forman D, Quirke P. The validity of the Royal College of Pathologists' colorectal cancer minimum dataset within a population. Br. J. Cancer 2007; 97; 1393-1398.
35. Kirsch R, Messenger DE, Riddell RH et al. Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am. J. Surg. Pathol. 2013; 37; 200-210.
36. Mekenkamp LJ, Heesterbeek KJ, Koopman M et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur. J. Cancer 2012; 48; 501-509.
37. Hugen N, Verhoeven RH, Radema SA et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann. Oncol. 2013; 24; 2819-2824.
38. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann. Oncol. 2014; 25; 651-657.
39. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am. J. Clin. Pathol. 2005; 123; 56-65.
40. Steele RJ, McClements P, Watling C et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61; 576-581.
41. Wu Y, Wu YY, Li S et al. TEM and conventional rectal surgery for T1 rectal cancer: a meta-analysis. Hepatogastroenterology 2011; 58; 364-368.
42. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in PT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy 2013; 45; 827-834.
43. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy 1993; 25; 455-461.
44. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985; 89; 328-336.
45. Ueno H, Hase K, Hashiguchi Y et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. J. Gastroenterol. 2014; 207; 70-77.
46. Maas M, Nelemans PJ, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11; 835-844.
47. Park SY, Chang HJ, Kim DY et al. Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy? Histopathology 2011; 59; 650-659.
48. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of CT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J. Clin. Oncol. 2007; 25; 4379-4386.
49. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I. Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int. J. Colorectal Dis. 2005; 20; 440-445.
50. Gosens MJ, Klaassen RA, Tan-Go I et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin. Cancer Res. 2007; 13; 6617-6623.
51. Perez RO, Habr-Gama A, Smith FM et al. Fragmented pattern of tumor regression and lateral intramural spread may influence margin appropriateness after TEM for rectal cancer following neoadjuvant CRT. J. Surg. Oncol. 2014; 109; 853-858.
52. Gopal P, Lu P, Ayers GD, Herline AJ, Washington MK. Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis. Mod. Pathol. 2014; 27; 1281-1287.
53. Duldulao MP, Lee W, Streja L et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis. Colon Rectum 2013; 56; 142-149.
54. Messenger DE, McLeod RS, Kirsch R. What impact has the introduction of a synoptic report for rectal cancer had on reporting outcomes for specialist gastrointestinal and nongastrointestinal pathologists? Arch. Pathol. Lab. Med. 2011; 135; 1471-1475.
55. Tong LL, Gao P, Wang ZN et al. Is PT2 subclassification feasible to predict patient outcome in colorectal cancer? Ann. Surg. Oncol. 2011; 18; 1389-1396.
56. Pollheimer MJ, Kornprat P, Pollheimer VS et al. Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int. J. Colorectal Dis. 2010; 25; 187-196.
57. Wittekind C, Greene FL, Henson DE, Hutter RVP, Sobin LH. TNM supplement: a commentary on uniform use. Chicester: John Wiley & Sons, 2003.
58. Wittekind C, Compton C, Brierley J, Sobin LH. TNM supplement; a commentary on uniform use. 4th ed. Chichester: John Wiley & Sons, 2012.
59. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Circhester: John Wiley & Sons, 2009.